Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease.

Clayton NP, Nelson CA, Weeden T, Taylor KM, Moreland RJ, Scheule RK, Phillips L, Leger AJ, Cheng SH, Wentworth BM.

Mol Ther Nucleic Acids. 2014 Oct 28;3:e206. doi: 10.1038/mtna.2014.57.

2.

Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease.

Taylor KM, Meyers E, Phipps M, Kishnani PS, Cheng SH, Scheule RK, Moreland RJ.

PLoS One. 2013;8(2):e56181. doi: 10.1371/journal.pone.0056181. Epub 2013 Feb 14.

3.

Species-specific differences in the processing of acid α-glucosidase are due to the amino acid identity at position 201.

Moreland RJ, Higgins S, Zhou A, VanStraten P, Cauthron RD, Brem M, McLarty BJ, Kudo M, Canfield WM.

Gene. 2012 Jan 1;491(1):25-30. doi: 10.1016/j.gene.2011.09.011. Epub 2011 Sep 22.

PMID:
21963446
4.

Induction of immune tolerance to a therapeutic protein by intrathymic gene delivery.

Chu Q, Moreland RJ, Gao L, Taylor KM, Meyers E, Cheng SH, Scheule RK.

Mol Ther. 2010 Dec;18(12):2146-54. doi: 10.1038/mt.2010.164. Epub 2010 Jul 27.

5.

Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.

Ashe KM, Taylor KM, Chu Q, Meyers E, Ellis A, Jingozyan V, Klinger K, Finn PF, Cooper CG, Chuang WL, Marshall J, McPherson JM, Mattaliano RJ, Cheng SH, Scheule RK, Moreland RJ.

Mol Genet Metab. 2010 Aug;100(4):309-15. doi: 10.1016/j.ymgme.2010.05.001. Epub 2010 May 5.

PMID:
20554235
6.

Role of viral hemagglutinin glycosylation in anti-influenza activities of recombinant surfactant protein D.

Hartshorn KL, Webby R, White MR, Tecle T, Pan C, Boucher S, Moreland RJ, Crouch EC, Scheule RK.

Respir Res. 2008 Sep 23;9:65. doi: 10.1186/1465-9921-9-65.

7.

Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor.

Moreland RJ, Jin X, Zhang XK, Decker RW, Albee KL, Lee KL, Cauthron RD, Brewer K, Edmunds T, Canfield WM.

J Biol Chem. 2005 Feb 25;280(8):6780-91. Epub 2004 Nov 1.

8.

cDNA cloning, DNA binding, and evolution of mammalian transcription factor IIIA.

Hanas JS, Hocker JR, Cheng YG, Lerner MR, Brackett DJ, Lightfoot SA, Hanas RJ, Madhusudhan KT, Moreland RJ.

Gene. 2002 Jan 9;282(1-2):43-52.

PMID:
11814676
9.

Elongin from Saccharomyces cerevisiae.

Koth CM, Botuyan MV, Moreland RJ, Jansma DB, Conaway JW, Conaway RC, Chazin WJ, Friesen JD, Arrowsmith CH, Edwards AM.

J Biol Chem. 2000 Apr 14;275(15):11174-80.

10.

Identification of a transcription factor IIIA-interacting protein.

Moreland RJ, Dresser ME, Rodgers JS, Roe BA, Conaway JW, Conaway RC, Hanas JS.

Nucleic Acids Res. 2000 May 1;28(9):1986-93.

11.

Dual roles for transcription factor IIF in promoter escape by RNA polymerase II.

Yan Q, Moreland RJ, Conaway JW, Conaway RC.

J Biol Chem. 1999 Dec 10;274(50):35668-75.

12.

A role for the TFIIH XPB DNA helicase in promoter escape by RNA polymerase II.

Moreland RJ, Tirode F, Yan Q, Conaway JW, Egly JM, Conaway RC.

J Biol Chem. 1999 Aug 6;274(32):22127-30.

13.

Mechanism of promoter escape by RNA polymerase II.

Conaway JW, Dvir A, Moreland RJ, Yan Q, Elmendorf BJ, Tan S, Conaway RC.

Cold Spring Harb Symp Quant Biol. 1998;63:357-64. No abstract available.

PMID:
10384300
14.

Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.

Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG Jr, Elledge SJ, Conaway RC, Harper JW, Conaway JW.

Science. 1999 Apr 23;284(5414):657-61.

16.

Rectal versus axillary temperatures.

Moreland RJ.

J Emerg Nurs. 1993 Dec;19(6):480. No abstract available.

PMID:
8309137

Supplemental Content

Loading ...
Support Center